"牯岭镇山上有100多家民宿、2000多张床位。"牯岭镇四级主任科员杨亚红介绍，为解决民宿行业自购 布草资金压力大、洗涤品质参差不齐等问题，牯岭镇创新推出"强社公司"运营模式，打造"带富工坊"， 构建"联建统筹+民宿出单+工坊接单"运营闭环体系，推动布草、一次性用品等资源精准对接。 "过去很多民宿主都是自行洗涤布草，消毒杀菌都只能依靠太阳，如今有了自动化洗涤设备，不仅使得 布草清洗更干净，还降低了清洗成本。"江西庐山迅洁洗涤有限公司负责人罗来澄介绍，目前已经与60 多家民宿、40多家酒店达成合作，提供布草洗涤、收送一条龙服务。 江西庐山：凝聚非公经济力量 共建"带富工坊" 中新网江西庐山9月16日电 (巫发阳 邓旻弘 崔平)初秋时节，走进江西庐山市牯岭镇，群峰笼罩在云雾之 间，古朴雅致的民宿藏在幽静的角落，等待五湖四海的游客入住体验。 除了布草公司，牯岭镇还引进了一次性用品供应公司，搭建了酒店用品一站式采购平台，使得民宿主可 以集中采购一次性用品，不仅实现了降本增效，还能够送货上门。 截至目前，牯岭镇"带富工坊"带动周边居民稳定就业50余人，季节性用工10余人。2025年，预计实现经 营收入300万元，助力村 ...

Core Viewpoint - The article discusses the challenges faced by businesses and individuals in the current economic climate, emphasizing the need for cost-cutting measures due to declining profits and increased difficulty in generating income [1]. Group 1: Economic Challenges - The impact of the COVID-19 pandemic has led to a sluggish real economy, resulting in layoffs and salary cuts for many companies [1]. - Business owners express that it has become increasingly difficult to secure orders, leading to thinner profit margins [1]. Group 2: Cost-Cutting Recommendations - The article suggests six items that should not be purchased to save money until the economy improves: - **Storage Boxes**: Excessive storage boxes are unnecessary; it is better to declutter and keep only essential items [3]. - **Cosmetics**: Hoarding cosmetics is wasteful; it is recommended to buy only what is needed and use it before purchasing more [4][6]. - **Clothing**: Many young people buy excessive new clothes; it is advised to keep a limited number of versatile outfits instead [8]. - **Personal Care Products**: Expensive shampoos and body washes are not necessary; affordable alternatives can provide similar quality [8]. - **Books**: Buying numerous books is impractical; borrowing from libraries or purchasing e-books is a more economical option [9]. - **Disposable Items**: Using reusable items instead of disposables can save money and reduce waste [11].

Financial Data and Key Metrics Changes - For Q1 2025, the company achieved revenue of $19.5 million, an 11% increase from $17.6 million in Q1 2024 [4][13] - Gross profit margin was reported at 76.1%, consistent with Q1 2024 [14] - GAAP diluted earnings per share increased by 16% to $0.37 from $0.32 in Q1 2024 [15] - Non-GAAP adjusted net income was $5.3 million or $0.42 per diluted share, up 17% from $4.6 million or $0.36 per diluted share in Q1 2024 [16] Business Line Data and Key Metrics Changes - Revenue from IV infusion pump systems grew 16% to $6 million, while disposable revenue increased 23% to $4.9 million [13][14] - Patient vital signs monitoring systems revenue remained steady at $6.5 million [14] - Service revenue remained stable at $1 million [14] Market Data and Key Metrics Changes - Domestic sales accounted for 82% of total revenue in Q1 2025, up from 76% in Q1 2024 [13] - Domestic revenue increased 19% to $16 million, while international sales declined 15% to $3.5 million [14] Company Strategy and Development Direction - The company is focused on increasing monitoring sales in 2025, anticipating a decline in pump revenues later in the year [22] - The new 3,870 MRIV pump is expected to contribute to revenue in 2026, with clearance anticipated in mid-2025 [10] - The company is nearing completion of a new facility, with full operations expected by July 2025 [11] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism regarding the impact of tariffs, noting that only 3% of revenue is linked to high-tariff sources [6][8] - The FDA's responsiveness has been positive, with ongoing interactions indicating progress towards device clearance [27] - The company expects Q2 2025 revenue guidance of $19.7 million to $19.9 million, with full-year revenue guidance of $78 million to $82 million [11][12] Other Important Information - Operating expenses increased to $9.4 million, primarily due to higher general and administrative costs [15] - Cash flow from operations was $4.3 million, up 10% from Q1 2024 [16] Q&A Session Summary Question: Inquiry about disposables performance - Management indicated that the strong disposable revenue was partly due to working down backlog and expects growth to align with capital growth [18][19] Question: Composition of bookings and monitoring sales recovery - Management confirmed strong bookings for monitoring systems in Q1 and early Q2, indicating confidence in recovery [21][24] Question: Status of FDA interactions and clearance timeline - Management provided updates on FDA interactions, indicating ongoing communication and a hopeful timeline for clearance within a few weeks [25][27]